The DOI matches its Crossref record; 136 of the 144 references it cites were found in a registry or an index; 187 of the 232 sources its claims cite were checked for support.
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Open accessAbstract
KRAS is a small GTPase that is among the most commonly mutated oncogenes in cancer. Here, we discuss KRAS biology, therapeutic avenues to target it, and mechanisms of resistance that tumors employ in response to KRAS inhibition. Several strategies are under investigation for inhibiting oncogenic KRAS, including small molecule compounds targeting specific KRAS mutations, pan-KRAS inhibitors, PROTACs, siRNAs, PNAs, and mutant KRAS-specific immunostimulatory strategies. A central challenge to therapeutic effectiveness is the frequent development of resistance to these treatments. Direct resistance mechanisms can involve KRAS mutations that reduce drug efficacy or copy number alterations that increase the expression of mutant KRAS. Indirect resistance mechanisms arise from mutations that can rescue mutant KRAS-dependent cells either by reactivating the same signaling or via alternative pathways. Further, non-mutational forms of resistance can take the form of epigenetic marks, transcriptional reprogramming, or alterations within the tumor microenvironment. As the possible strategies to inhibit KRAS expand, understanding the nuances of resistance mechanisms is paramount to the development of both enhanced therapeutics and innovative drug combinations.
Overview
CoChat Summary
TL;DR
This review summarizes KRAS biology, the main classes of KRAS-targeted therapies, and the many ways tumors evade them. It emphasizes that resistance is common after KRAS inhibition and that combination strategies and new drug modalities are needed to improve durability.
Key findings
- KRAS mutations are reported in 25–30% of all human cancers, including about 19% of NSCLCs, 40% of CRCs, and 73% of PDAC cases.
- For KRAS G12C inhibitors, clinical benefit is limited by relapse: in NSCLC, median response durations were in the 6–7 month range before resistance emerged.
- In a sotorasib-treated patient study, 7% developed KRAS G12C amplifications; in post-sotorasib tumors, 14% had an additional or alternative KRAS point mutation.
- Multiple inhibitor classes are discussed as active or promising, including sotorasib and adagrasib for G12C, MRTX1133 for G12D, BI-2865 as a pan-KRAS inhibitor, and RMC-6291 as a CYPA-recruiting strategy; several are noted as being in clinical trials.
Methods
- The paper is a narrative review of KRAS biology, therapeutic strategies, and resistance mechanisms.
- It synthesizes evidence from preclinical models (cell lines, mouse models, xenografts, PDXs) and clinical studies/trials of KRAS-targeted agents.
- The main analysis is a mechanism-based synthesis organized into KRAS regulation, inhibitor classes, immunotherapies, and mutational/non-mutational resistance pathways.
Limitations
- The paper does not present a new primary dataset or perform a formal meta-analysis; this is evident from the text.
- It notes that many strategies remain preclinical or in ongoing clinical trials, so clinical effectiveness is not yet established; this is stated in the paper.
- The text makes evident that several conclusions are based on heterogeneous models (cell lines, murine xenografts, patient samples, and basket trials), which limits direct comparability across findings; this is evident from the text.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 (a) Domain architecture of KRAS; (b) frequency of KRAS mutation by disease and location. Specific amino acid changes at G12 are color-coded by relative frequency. Mutation data were downloaded from the curated set of non-redundant samples in cBioportal [1,2]. NSCLC, non-small cell lung cancer; CRC, colorectal carcinoma; PDAC, pancreatic ductal adenocarcinoma; aa, amino acid. (c) Pie charts showing the frequency of KRAS mutations in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. G12 mutations are color-coded as in (b). The other category represents KRAS mutations that are not G12C, G12D, G12R, G12V, or G12S.](https://figures.cochat.ai/paper-figures/43cf2582983d48248209c966d4ee5367/kras-biology-inhibition-and-mechanisms-of-inhibitor-resistance-figure-1.jpg)



Verification
Claims the paper makes
132 Valid · 9 Not valid · 25 Not checked · 30 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A mesenchymal-like differentiation state can act as a resistance mechanism to KRAS inhibitors [126,128,130].”
§ KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance > 5. Non-Mutational Resistance > 5.3. Epithelial-to-Mesenchymal Transition
What the sources say
- Not checked — no full text of the sourcecites [126] Adachi, 2023, Scribble Mis-Localization Induces Adaptive Resistance to KRAS G12C Inhibitors through Feedback Activation of MAPK Signaling Mediated by YAP-Induced MRAS, Nat. Cancer source
- Supportedcites [128] Solanki, 2021, Cell Type–Specific Adaptive Signaling Responses to KRASG12C Inhibition, Clin. Cancer Res. source
The Results section (‘FGFR1 activation drives resistance to ARS-1620 in H1792 cells’; page not supplied) reports that inducing epithelial-to-mesenchymal transition reduced sensitivity to the KRASG12C inhibitor ARS-1620. The Discussion also identifies resistance-associated FGFR1 and AXL signaling in mesenchymal models. These findings support the claim that a mesenchymal-like state can contribute to resistance, specifically for KRASG12C inhibition. (LLM, conf=0.92)
- Supportedcites [130] Kapoor, 2014, Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer, Cell source
The Results section (page unavailable) links quasimesenchymal pancreatic tumors with lower KRAS dependence and reports that an epithelial-to-mesenchymal transition program can drive KRAS-independent growth. The Discussion (page unavailable) identifies a YAP1-mediated program as a resistance mechanism to KRAS inhibition. The experiments used genetic KRAS extinction rather than a KRAS-inhibitor drug, but the paper explicitly discusses the implications for such drugs. (LLM, conf=0.86)
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“G12C and G12V mutations are predominant in lung adenocarcinomas with smoking-associated mutational signatures [30,32].”
§ KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance > 1. Introduction > 1.5. KRAS Mutations
What the sources say
- Partly supportedcites [30] Cook, 2021, The Origins and Genetic Interactions of KRAS Mutations Are Allele- and Tissue-Specific, Nat. Commun. sourceExperimental — accuracy not yet measured
The Results section, “The KRAS alleles have different mutagenic origins” (page unavailable), attributes G12A, G12C and G12V mutations in lung adenocarcinoma primarily to tobacco smoke. Another Results section identifies G12C as the most common KRAS allele in lung adenocarcinoma, but the copy does not establish that G12V is also predominant. (LLM, conf=0.84)
- Partly supportedcites [32] Haigis, 2017, KRAS Alleles: The Devil Is in the Detail, Trends. Cancer sourceExperimental — accuracy not yet measured
The “KRAS Allelic Variation” section says G12C and G12V are the most frequent KRAS mutations in non-small cell lung cancer and arise from a classical smoking-induced transversion. It does not establish their predominance specifically in lung adenocarcinomas with smoking-associated mutational signatures. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Specific KRAS mutations show characteristic patterns of tissue preference (Figure 1b,c).”
§ KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance > 1. Introduction > 1.5. KRAS Mutations
What the sources say
- Supportedcites [30] Cook, 2021, The Origins and Genetic Interactions of KRAS Mutations Are Allele- and Tissue-Specific, Nat. Commun. source
The Results section, “KRAS alleles are non-uniformly distributed across cancers” (page unavailable), reports distinct allele-frequency patterns across four cancer types. It identifies G12C enrichment in lung adenocarcinoma, G13D and A146T enrichment in colorectal adenocarcinoma, and a high frequency of G12R in pancreatic adenocarcinoma, supporting the claimed tissue preference. (LLM, conf=0.94)
- Supportedcites [32] Haigis, 2017, KRAS Alleles: The Devil Is in the Detail, Trends. Cancer source
The “KRAS Allelic Variation” section states that the frequency of specific KRAS alleles depends on cancer type. It identifies G12C and G12V as most frequent in NSCLC and describes codon 117 and 146 mutations as nearly selective for colorectal cancer. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In 2022, the Shokat lab introduced a novel KRAS G12S-selective covalent inhibitor [59].”
§ KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance > 2. Targeted KRAS Inhibitors > 2.4. KRAS G12S and KRAS G12R Tool Compounds
What the sources say
- Supportedcites [59] Zhang, 2022, Chemical Acylation of an Acquired Serine Suppresses Oncogenic Signaling of K-Ras(G12S), Nat. Chem. Biol. source
The Abstract reports the discovery of small molecules that covalently target K-Ras(G12S) while sparing wild-type K-Ras. The Discussion describes their allele-specific suppression of oncogenic signaling. The cited 2022 paper includes Shokat among its authors. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“While these inhibitors are each approved against various malignancies, mutant KRAS is not typically a specific biomarker [45].”
§ KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance > 2. Targeted KRAS Inhibitors > 2.1. KRAS as a Therapeutic Target
What the sources say
- Supportedcites [45] Tang, 2021, Oncogenic KRAS Blockade Therapy: Renewed Enthusiasm and Persistent Challenges, Mol. Cancer source
The Indirect KRAS suppression strategies section (page unavailable) says several RAF and MEK inhibitors are approved for BRAF-mutant tumors, not KRAS-mutant tumors; it also describes approved PI3K inhibitors for other indications. This supports the point that mutant KRAS is not typically the biomarker for those approved uses. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
123 more claims · 89 with their cited sources checked
Create a free account to see all 196 claims and to verify the 11 references still open.
- It may state two separate claims as one. 57
- Probably not a substantial claim. 15
- Borderline: one of the tests for a substantial claim is unclear. 1
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 3×
“KRAS mutations are implicated in 25–30% of all human cancers, about 19% of non-small cell lung cancers (NSCLCs), about 40% of colorectal cancers (CRCs), and about 73% of pancreatic ductal adenocarcinoma (PDAC) cases (Figure 1) [1,2].”
BackgroundMethodIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 3×
“KRAS mutations are implicated in 25–30% of all human cancers, about 19% of non-small cell lung cancers (NSCLCs), about 40% of colorectal cancers (CRCs), and about 73% of pancreatic ductal adenocarcinoma (PDAC) cases (Figure 1) [1,2].”
BackgroundMethodMarshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“Pathways downstream of KRAS ultimately promote proliferation and cell survival, which are key to the growth and maintenance of cancer cells when KRAS is inappropriately activated.”
BackgroundA Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · cited 1×
“Furthermore, the inhibition of KRAS can activate MRAS in a YAP-dependent manner, leading to a more mesenchymal marker profile [126].”
BackgroundSakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · cited 1×
“These vaccines are designed to induce antigen-presenting cells to display mutant KRAS, stimulating attacks by cytotoxic T-cells against cancer cells expressing mutant KRAS neoantigen [78–80].”
BackgroundK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892 · cited 2×
“Onco-genic KRAS has been identified as a key player in inducing significant metabolic changes in cells and can drive alterations in various metabolic pathways, including glycolysis, glu-Curr taminolysis, and micropinocytosis [24].”
BackgroundSotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811 · cited 1×
“Pathways downstream of KRAS ultimately promote proliferation and cell survival, which are key to the growth and maintenance of cancer cells when KRAS is inappropriately activated.”
BackgroundDrug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., Galeas, J., Dhruv, H. D., Berens, M. E., Schreiber, S. L., et al. (2017) · Nature · doi:10.1038/nature24297 · Cited by 1,799
Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity
Weinberg, F., Hamanaka, R., Wheaton, W. W., Weinberg, S., Joseph, J., Lopez, M., Kalyanaraman, B., Mutlu, G. M., Budinger, G. R. S., & Chandel, N. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003428107 · Cited by 1,742 · cited 1×
“Notably, lung adenocarcinomas in smokers exhibit a higher frequency of G to T transversions compared to those in nonsmokers [35].”
BackgroundKRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 1×
“In mutant KRAS cells, the presence of the wildtype allele can drive resistance to downstream pathway inhibitors including MEK [108].”
BackgroundMacropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., et al. (2013) · Nature · doi:10.1038/nature12138 · Cited by 1,683 · cited 1×
“One exogenous cause of the increased prevalence of G12C mutations in lung cancers is benzo[a]pyrene-diol epoxide (BPDE), a carcinogen found in cigarettes [33,34].”
BackgroundEpithelial-Mesenchymal Transitions
Kang, Y., & Massagué, J. (2004) · Cell · doi:10.1016/j.cell.2004.07.011 · Cited by 1,525 · cited 1×
“The efficacy of multiple KRAS G12Ci methodologies including the PROTAC LC-2 and covalent inhibitor ARS-1620 were impaired by high expression of Multi-Drug Resistance 1 (MDR1) activity, a classic drug efflux mechanism of resistance [134,135].”
MethodT-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368 · cited 2×
“Clinical evaluations of KRAS inhibitors, sotorasib and adagrasib, were conducted as basket trials and included solid tumors with KRAS G12C regardless of the tissue of origin.”
BackgroundCatalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356 · cited 1×
“A phase 2 clinical trial is investigating the delivery of KRAS-mutant neoantigens along with immune-activating checkpoint inhibitors in KRAS-mutant solid tumors as a method of training the immune system to target KRAS-mutant cells [81].”
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · cited 4×
“Gain-of-function screens of epigenetic regulators in KRAS-mutant PDAC models identified HDAC5 as a driver of resistance to KRAS inhibition within the tumor microenvironment [54].”
BackgroundInfluentialAcquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247 · cited 3×
“The ability of persister cells to transition back and forth between sensitive and insensitive states demonstrates that the mechanisms underlying their drug resistance are not driven by permanent genetic changes [115,118,119].”
BackgroundKRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127 · cited 2×
“One of the main rewired metabolic pathways is glucose metabolism.”
BackgroundRAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · cited 1×
“In the early stages of treatment, non-mutational DTP cell lines can enter a quiescent non-growth state [115,118,120].”
BackgroundAdagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061 · cited 1×
“KRAS G12C amplification was a consistent resistance mechanism that increased in frequency over the duration of the treatment of CRC patients and cell lines treated with combinations of KRAS and EGFR inhibitors [101].”
BackgroundHancock, J. F., Paterson, H., & Marshall, C. J. (1990) · Cell · doi:10.1016/0092-8674(90)90294-o · Cited by 1,059
Milburn, M. V., Tong, L., deVos, A. M., Brünger, A., Yamaizumi, Z., Nishimura, S., & Kim, S.-H. (1990) · Science · doi:10.1126/science.2406906 · Cited by 1,059
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884 · cited 1×
“Sotorasib and adagrasib, two prominent members of this class, were effective at halting the growth of G12C-mutant cancer cells in 2-dimensional, 3-dimensional, and xenograft models, clearing the path for clinical trials [48–51].”
BackgroundSingh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841 · cited 1×
“Furthermore, the inhibition of KRAS can activate MRAS in a YAP-dependent manner, leading to a more mesenchymal marker profile [126].”
BackgroundHuman Sos1: a Guanine Nucleotide Exchange Factor for Ras that Binds to GRB2
Chardin, P., Camonis, J. H., Gale, N. W., van Aelst, L., Schlessinger, J., Wigler, M. H., & Bar-Sagi, D. (1993) · Science · doi:10.1126/science.8493579 · Cited by 797
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · cited 1×
“Sotorasib treatment not only increased the intratumoral concentration of chemokines that promote immune infiltration but also induced the expression of neoantigens on MHC class I, leading to improved antigen recognition and potentially a more robust, long-lasting antitumor T-cell response.”
BackgroundKRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744 · cited 1×
“Cell lines resistant to PROTACs were rendered sensitive by genetic and pharmacological MDR1 inhibition, suggesting a combinatorial strategy involving KRAS PROTACs and MDR1 inhibitors [134].”
BackgroundOncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721 · cited 1×
“MYCN and EGFR can be amplified in double minutes in neuroblastoma and breast carcinomas, respectively, raising the possibility that KRAS G12C amplifications may arise in a similar way in NSCLC and CRC [104,105].”
BackgroundYap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716 · cited 1×
“Cell lines resistant to PROTACs were rendered sensitive by genetic and pharmacological MDR1 inhibition, suggesting a combinatorial strategy involving KRAS PROTACs and MDR1 inhibitors [134].”
BackgroundSH2-Containing Phosphotyrosine Phosphatase as a Target of Protein-Tyrosine Kinases
Feng, G.-S., Hui, C.-C., & Pawson, T. (1993) · Science · doi:10.1126/science.8096088 · Cited by 661
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02052 · Cited by 653
Wang, T., Yu, H., Hughes, N. W., Liu, B., Kendirli, A., Klein, K., Chen, W. W., Lander, E. S., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.01.013 · Cited by 632 · cited 2×
“Quiescence can lead to insensitivity to drugs targeting essential growth pathways, as these pathways become less critical in dormant cells [115].”
BackgroundRas signalling on the endoplasmic reticulum and the Golgi
Chiu, V. K., Bivona, T., Hach, A., Sajous, J. B., Silletti, J., Wiener, H., Johnson, R. L., Cox, A. D., & Philips, M. R. (2002) · Nature Cell Biology · doi:10.1038/ncb783 · Cited by 594 · cited 1×
“In addition to its direct inhibitory effect on KRAS-mutant cancer cells, sotorasib was found to promote antitumor immunity in a syngeneic CT-26 KRAS G12C colon cancer model by creating a pro-inflammatory tumor microenvironment [48].”
BackgroundConvergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588 · cited 1×
“In mutant KRAS cells, the presence of the wildtype allele can drive resistance to downstream pathway inhibitors including MEK [108].”
BackgroundNegative feedback regulation of the ERK1/2 MAPK pathway
Lake, D., Corrêa, S. A. L., & Müller, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2297-8 · Cited by 565
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02007-7 · Cited by 553 · cited 2×
“In 2022, the Shokat lab introduced a novel KRAS G12S-selective covalent inhibitor [59].”
BackgroundRapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543 · cited 6×
“Combining the KRAS G12D inhibitor MRTX1133 with one or more immune checkpoint blockades was more effective than MRTX1133 as a single agent in a murine model of PDAC [132].”
BackgroundInfluentialPan-KRAS Inhibitor Disables Oncogenic Signalling and Tumour Growth
Kim, D., Herdeis, L., Rudolph, D., Zhao, Y., Böttcher, J., Vides, A., Ayala-Santos, C. I., Pourfarjam, Y., Cuevas-Navarro, A., Xue, J. Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06123-3 · Cited by 534 · cited 7×
“In KRAS inhibitor-resistant tumors, genetic alterations observed in upstream regulators included transmembrane growth factor receptors EGFR and FGFR2/3 as well as the KRAS-regulating GAP protein NF1 [102].”
BackgroundInfluentialTanaka, N., Lin, J. J., Li, C., Ryan, M. B., Zhang, J., Kiedrowski, L. A., Michel, A. G., Syed, M. U., Fella, K. A., Sakhi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0365 · Cited by 527 · cited 2×
“These included two processing enzymes involved in membrane targeting, RCE1 and ICMT, as well as RAS pathway members including SHOC2, RAF1, ERK, RSK1, and PREX1 [112].”
BackgroundStudying clonal dynamics in response to cancer therapy using high-complexity barcoding
Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507 · cited 1×
“A mesenchymal-like differentiation state can act as a resistance mechanism to KRAS inhibitors [126,128,130].”
BackgroundEGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504 · cited 3×
“This increased acidity can induce intracellular acidosis, hindering the antitumor functions of immune cells and thereby compromising immune surveillance, ultimately driving cancer progression.”
BackgroundDiverse alterations associated with resistance to KRAS(G12C) inhibition
Zhao, Y., Murciano-Goroff, Y. R., Xue, J. Y., Ang, A., Lucas, J., Mai, T. T., Da Cruz Paula, A. F., Saiki, A. Y., Mohn, D., Achanta, P., et al. (2021) · Nature · doi:10.1038/s41586-021-04065-2 · Cited by 479 · cited 9×
“Genome-wide CRISPR screens in untreated KRAS-mutant, NRAS-mutant, and wild-type cell lines identified several classes of synthetic lethalities with mutant KRAS.”
BackgroundInfluentialTargeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACs
Bond, M. J., Chu, L., Nalawansha, D. A., Li, K., & Crews, C. M. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00411 · Cited by 450 · cited 1×
“Building on the momentum of KRAS-specific cancer vaccines, a recent study introduced an innovative intranasal vaccine targeting NSCLC based on a mix of G12D mutant and wildtype KRAS peptides and enhanced by a nanoemulsion adjuvant [82].”
BackgroundHainaut, P. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.367 · Cited by 375
KRAS Alleles: The Devil Is in the Detail
Haigis, K. M. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.08.006 · Cited by 373
Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer
Kemp, S. B., Cheng, N., Markosyan, N., Sor, R., Kim, I.-K., Hallin, J., Shoush, J., Quinones, L., Brown, N. V., Bassett, J. B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1066 · Cited by 370 · cited 1×
“Furthermore, the Shokat lab identified electrophiles with the potential for developing G12R-selective inhibitors [60].”
BackgroundDifferential regulation of rasGAP and neurofibromatosis gene product activities
Bollag, G., & McCormick, F. (1991) · Nature · doi:10.1038/351576a0 · Cited by 341
Molecular epidemiology and diagnostics of KRAS mutations in human cancer
Timar, J., & Kashofer, K. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09915-5 · Cited by 334
FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC
Nakajima, E. C., Drezner, N., Li, X., Mishra-Kalyani, P. S., Liu, Y., Zhao, H., Bi, Y., Liu, J., Rahman, A., Wearne, E., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3074 · Cited by 333
Mutant KRAS is a druggable target for pancreatic cancer
Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314307110 · Cited by 295 · cited 1×
“The avidity of PNAs for a single strand of”
BackgroundCurrent Development Status of MEK Inhibitors
Cheng, Y., & Tian, H. (2017) · Molecules · doi:10.3390/molecules22101551 · Cited by 291 · cited 1×
“Sotorasib administration led to the tumor infiltration of CD8 T-cells, macrophages, and dendritic cells, which were further amplified by the combination with anti-PD-1 therapy.”
BackgroundLipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging
Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282 · cited 1×
“The avidity of PNAs for a single strand of”
BackgroundThe Son of sevenless Gene Product: a Putative Activator of Ras
Bonfini, L., Karlovich, C. A., Dasgupta, C., & Banerjee, U. (1992) · Science · doi:10.1126/science.1736363 · Cited by 272
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201414 · Cited by 265 · cited 1×
“An alternative preclinical strategy being tested is combining inhibitors of TEAD proteins with KRASi, preventing feedback reactivation [125,127].”
MethodChemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Schulze, C. J., Seamon, K. J., Zhao, Y., Yang, Y. C., Cregg, J., Kim, D., Tomlinson, A., Choy, T. J., Wang, Z., Sang, B., et al. (2023) · Science · doi:10.1126/science.adg9652 · Cited by 264 · cited 11×
“Saturating mutagenesis screens and looking for point mutations in KRAS that produced resistance to CYPA recruiting compound RMC-6291 identified E31A, D33A, or E37A as resistance mutations that in combination decreased drug efficacy.”
BackgroundInfluentialMisale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., Russo, M., Buscarino, M., Lazzari, L., Sartore-Bianchi, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007947 · Cited by 263 · cited 2×
“This increased acidity can induce intracellular acidosis, hindering the antitumor functions of immune cells and thereby compromising immune surveillance, ultimately driving cancer progression.”
BackgroundMahadevan, K. K., McAndrews, K. M., LeBleu, V. S., Yang, S., Lyu, H., Li, B., Sockwell, A. M., Kirtley, M. L., Morse, S. J., Moreno Diaz, B. A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.002 · Cited by 258 · cited 2×
“…G12C inhibitors against sensitive mouse tumors, possibly because they prevent feedback reactivation driven by the loss of ERK-mediated EGFR repression when KRAS activity is abrogated and/or because SHP2 inhibitors drive KRAS to be in the G12C inhibitor-sensitive GDP-bound state of KRAS [50,133].”
BackgroundNMR-based functional profiling of RASopathies and oncogenic RAS mutations
Smith, M. J., Neel, B. G., & Ikura, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218173110 · Cited by 257
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
Wang, Q. J., Yu, Z., Griffith, K., Hanada, K.-I., Restifo, N. P., & Yang, J. C. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0188 · Cited by 240 · cited 1×
“Clinical evaluations of KRAS inhibitors, sotorasib and adagrasib, were conducted as basket trials and included solid tumors with KRAS G12C regardless of the tissue of origin.”
BackgroundAtypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
Hobbs, G. A., Baker, N. M., Miermont, A. M., Thurman, R. D., Pierobon, M., Tran, T. H., Anderson, A. O., Waters, A. M., Diehl, J. N., Papke, B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1006 · Cited by 231
Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00577-0 · Cited by 215 · cited 1×
“Specifically, HDAC5 suppresses SOCS3, boosting CCL2 and CCL7 expression.”
Feig, L. A., & Cooper, G. M. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.6.2472 · Cited by 213
Distribution of KRAS G12C Somatic Mutations across Race, Sex, and Cancer Type
Nassar, A. H., Adib, E., & Kwiatkowski, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2030638 · Cited by 210
The origins and genetic interactions of KRAS mutations are allele- and tissue-specific
Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J., & Haigis, K. M. (2021) · Nature Communications · doi:10.1038/s41467-021-22125-z · Cited by 208
KRAS4A directly regulates hexokinase 1
Amendola, C. R., Mahaffey, J. P., Parker, S. J., Ahearn, I. M., Chen, W.-C., Zhou, M., Court, H., Shi, J., Mendoza, S. L., Morten, M. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1832-9 · Cited by 203 · cited 1×
“Most KRAS mutations are deficient for intrinsic hydrolysis; however, KRAS G12C maintains much of its intrinsic hydrolysis activity.”
BackgroundGTP-Dependent K-Ras Dimerization
Muratcioglu, S., Chavan, T. S., Freed, B. C., Jang, H., Khavrutskii, L., Freed, R. N., Dyba, M. A., Stefanisko, K., Tarasov, S. G., Gursoy, A., et al. (2015) · Structure · doi:10.1016/j.str.2015.04.019 · Cited by 202 · cited 2×
“Onco-genic KRAS has been identified as a key player in inducing significant metabolic changes in cells and can drive alterations in various metabolic pathways, including glycolysis, glu-Curr taminolysis, and micropinocytosis [24].”
BackgroundTissue-Specific Oncogenic Activity of KRASA146T
Poulin, E. J., Bera, A. K., Lu, J., Lin, Y.-J., Strasser, S. D., Paulo, J. A., Huang, T. Q., Morales, C., Yan, W., Cook, J., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1220 · Cited by 197
K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling
Wang, M.-T., Holderfield, M., Galeas, J., Delrosario, R., To, M. D., Balmain, A., & McCormick, F. (2015) · Cell · doi:10.1016/j.cell.2015.10.041 · Cited by 196
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer
Burgess, M. R., Hwang, E., Mroue, R., Bielski, C. M., Wandler, A. M., Huang, B. J., Firestone, A. J., Young, A., Lacap, J. A., Crocker, L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.020 · Cited by 183
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Bergö, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18829 · Cited by 180 · cited 1×
“In 2021, the FDA approved sotorasib for the treatment of adult patients with KRAS G12C-mutated NSCLC, while adagrasib received similar approval the following year [48,50–53].”
BackgroundInactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Bergo, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200418829 · Cited by 180
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177 · cited 2×
“…as siG12D-LODER, which is in clinical trials against KRAS G12D-driven Each siRNA is then processed by the endogenous RNA -induced silencing complex prior to binding to the target RNA, in this case, KRAS, thereby inhibiting translation and promoting mRNA degradation [66– 68]. pancreatic cancer [70].”
BackgroundKRAS G12C inhibition produces a driver-limited state revealing collateral dependencies
Lou, K., Steri, V., Ge, A. Y., Hwang, Y. C., Yogodzinski, C. H., Shkedi, A. R., Choi, A. L. M., Mitchell, D. C., Swaney, D. L., Hann, B., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw9450 · Cited by 175 · cited 1×
“Proposals for combination therapies aim to address many of these resistance mechanisms.”
BackgroundDNA replication fidelity and cancer
Preston, B. D., Albertson, T. M., & Herr, A. J. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.009 · Cited by 160 · cited 1×
“In mutant KRAS cells, the presence of the wildtype allele can drive resistance to downstream pathway inhibitors including MEK [108].”
BackgroundChemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile
Zhang, Z., Morstein, J., Ecker, A. K., Guiley, K. Z., & Shokat, K. M. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c05377 · Cited by 159 · cited 1×
“Murine xenograft experiments demonstrated efficacy against grafted cell lines and a PDX driven by KRAS G12C, G12D, G12V, and A146V without causing significant body weight loss.”
BackgroundKRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
Mao, Z., Xiao, H., Shen, P., Yang, Y., Xue, J., Yang, Y., Shang, Y., Zhang, L., Li, X., Zhang, Y., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00368-w · Cited by 158
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
Hou, P., Kapoor, A., Zhang, Q., Li, J., Wu, C.-J., Li, J., Lan, Z., Tang, M., Ma, X., Ackroyd, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0597 · Cited by 154 · cited 2×
“An alternative preclinical strategy being tested is combining inhibitors of TEAD proteins with KRASi, preventing feedback reactivation [125,127].”
BackgroundMethodChemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S)
Zhang, Z., Guiley, K. Z., & Shokat, K. M. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01065-9 · Cited by 153 · cited 4×
“The G12C inhibitor BI-0474 scaffold was used to develop the pan-KRAS inhibitor BI-2865, which non-covalently binds to KRAS-GDP with high affinity while sparing wildtypes HRAS and NRAS [62].”
MethodInfluentialMolecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Yaeger, R., Mezzadra, R., Sinopoli, J., Bian, Y., Marasco, M., Kaplun, E., Gao, Y., Zhao, H., Paula, A. D. C., Zhu, Y., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0405 · Cited by 144 · cited 5×
“The findings emphasize the TME’s role in resistance and suggest therapeutic strategies like combining TGF β or CCL2/CCL7-CCR2 targeting with KRAS inhibitors [54].”
BackgroundMethodInfluentialTargeting the Raf kinases in human cancer: the Raf dimer dilemma
Durrant, D., & Morrison, D. K. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.399 · Cited by 144 · cited 1×
“Pathways downstream of KRAS ultimately promote proliferation and cell survival, which are key to the growth and maintenance of cancer cells when KRAS is inappropriately activated.”
BackgroundThe drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
Kurimchak, A. M., Herrera-Montávez, C., Montserrat-Sangrà, S., Araiza-Olivera, D., Hu, J., Neumann-Domer, R., Kuruvilla, M., Bellacosa, A., Testa, J. R., Jin, J., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2707 · Cited by 136 · cited 2×
“Investigating the molecular and genetic underpinnings of treatment resistance can provide a roadmap to a future where these cancers are broadly more treatable.”
BackgroundMechanisms of Resistance to KRASG12C Inhibitors
Dunnett-Kane, V., Nicola, P. A., Blackhall, F. H., & Lindsay, C. R. (2021) · Cancers · doi:10.3390/cancers13010151 · Cited by 131
The role of wild type RAS isoforms in cancer
Zhou, B., Der, C. J., & Cox, A. D. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.07.012 · Cited by 130
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
Lv, X., Lu, X., Cao, J., Luo, Q., Ding, Y., Peng, F., Pataer, A., Lu, D., Han, D., Malmberg, E., et al. (2023) · Science · doi:10.1126/science.abn4180 · Cited by 123 · cited 7×
“CRISPRi screens using the precursor G12C inhibitor ARS-1620 in lung and pancreatic cancer cells identified a broad range of genes both core (SHP2) and ancillary (CDK4) to RAS function as collateral dependency genes whose targeting may potentiate KRASi in resistant cells [113].”
BackgroundInfluentialTumorigenic activity and therapeutic inhibition of Rheb GTPase
Mavrakis, K. J., Zhu, H., Silva, R. L. A., Mills, J. R., Teruya‐Feldstein, J., Lowe, S. W., Tam, W., Pelletier, J., & Wendel, H. (2008) · Genes & Development · doi:10.1101/gad.1690808 · Cited by 123
The effects of mutational processes and selection on driver mutations across cancer types
Temko, D., Tomlinson, I. P. M., Severini, S., Schuster-Böckler, B., & Graham, T. A. (2018) · Nature Communications · doi:10.1038/s41467-018-04208-6 · Cited by 115
Bear, A. S., Blanchard, T., Cesare, J., Ford, M. J., Richman, L. P., Xu, C., Baroja, M. L., McCuaig, S., Costeas, C., Gabunia, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24562-2 · Cited by 113 · cited 1×
“The data from both CodeBreak 100 for sotorasib and KRYSTAL-1 for adagrasib led to the approval of these inhibitors to treat G12C-mutant NSCLC [51,53,94].”
BackgroundDevelopment of siRNA Payloads to Target KRAS -Mutant Cancer
Yuan, T. L., Fellmann, C., Lee, C.-S., Ritchie, C. D., Thapar, V., Lee, L. C., Hsu, D. J., Grace, D., Carver, J. O., Zuber, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0900 · Cited by 113
Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells
De Conti, G., Dias, M. H., & Bernards, R. (2021) · Cancers · doi:10.3390/cancers13051118 · Cited by 111 · cited 1×
“Furthermore, the inhibition of KRAS can activate MRAS in a YAP-dependent manner, leading to a more mesenchymal marker profile [126].”
BackgroundCell Type–Specific Adaptive Signaling Responses to KRASG12C Inhibition
Solanki, H. S., Welsh, E. A., Fang, B., Izumi, V., Darville, L., Stone, B., Franzese, R., Chavan, S., Kinose, F., Imbody, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3872 · Cited by 106 · cited 2×
“This transport protein exports small drug molecules out of target cells, preventing long-term inhibition.”
BackgroundDrosten, M., Sum, E. Y. M., Lechuga, C. G., Simón-Carrasco, L., Jacob, H. K. C., García-Medina, R., Huang, S., Beijersbergen, R. L., Bernards, R., & Barbacid, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417549111 · Cited by 103 · cited 1×
“Drug-Tolerant Persister (DTP) cells can derive from pre-treatment stochastic expression variability in cell populations, or from treatment-induced changes in transcriptional profiles or epigenetic markers [115,117,118].”
BackgroundThe G protein signaling regulator RGS3 enhances the GTPase activity of KRAS
Li, C., Vides, A., Kim, D., Xue, J. Y., Zhao, Y., & Lito, P. (2021) · Science · doi:10.1126/science.abf1730 · Cited by 103
Dobson, S. M., García-Prat, L., Vanner, R. J., Wintersinger, J., Waanders, E., Gu, Z., McLeod, J., Gan, O. I., Grandal, I., Payne-Turner, D., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1059 · Cited by 94 · cited 1×
“A mesenchymal-like differentiation state can act as a resistance mechanism to KRAS inhibitors [126,128,130].”
BackgroundAdachi, Y., Kimura, R., Hirade, K., Yanase, S., Nishioka, Y., Kasuga, N., Yamaguchi, R., & Ebi, H. (2023) · Nature Cancer · doi:10.1038/s43018-023-00575-2 · Cited by 93 · cited 3×
“Specifically, HDAC5 suppresses SOCS3, boosting CCL2 and CCL7 expression.”
BackgroundTreatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
O’Sullivan, É., Keogh, A., Henderson, B., Finn, S. P., Gray, S. G., & Gately, K. A. (2023) · Cancers · doi:10.3390/cancers15061635 · Cited by 92
RAS and beyond: the many faces of the neurofibromatosis type 1 protein
Anastasaki, C., Orozco, P., & Gutmann, D. H. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049362 · Cited by 86 · cited 1×
“In the early stages of treatment, non-mutational DTP cell lines can enter a quiescent non-growth state [115,118,120].”
BackgroundOncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80 · cited 1×
“Sotorasib administration led to the tumor infiltration of CD8 T-cells, macrophages, and dendritic cells, which were further amplified by the combination with anti-PD-1 therapy.”
BackgroundNagasaka, M., Potugari, B. R., Nguyen, A., Sukari, A. W., Azmi, A. S., & Ou, S. I. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102309 · Cited by 80
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade
Sehgal, K., Portell, A. J., Ivanova, E. V., Lizotte, P. H., Mahadevan, N. R., Greene, J. R., Vajdi, A., Gurjao, C., Teceno, T. J., Taus, L. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135038 · Cited by 79 · cited 1×
“Furthermore, the inhibition of KRAS can activate MRAS in a YAP-dependent manner, leading to a more mesenchymal marker profile [126].”
BackgroundChaft, J. E., Litvak, A., Arcila, M. E., Patel, P., D'Angelo, S. P., Krug, L. M., Rusch, V., Mattson, A., Coeshott, C., Park, B., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.06.002 · Cited by 78
Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
Hattori, T., Maso, L., Araki, K. Y., Koide, A., Hayman, J., Akkapeddi, P., Bang, I., Neel, B. G., & Koide, S. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1074 · Cited by 72
Cho, K., Casteel, D. E., Prakash, P., Tan, L., van der Hoeven, D., Salim, A. A., Kim, C., Capon, R. J., Lacey, E., Cunha, S. R., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00365-16 · Cited by 68
Bifunctional Small‐Molecule Ligands of K‐Ras Induce Its Association with Immunophilin Proteins
Zhang, Z., & Shokat, K. M. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201910124 · Cited by 66
Disease-Causing Mutations in the G Protein Gαs Subvert the Roles of GDP and GTP
Hu, Q., & Shokat, K. M. (2018) · Cell · doi:10.1016/j.cell.2018.03.018 · Cited by 65 · cited 1×
“Interestingly, in KRAS wildtype cells, the compound was able to prevent the KRAS–RAF interaction; however, the inhibition of p-ERK and growth were markedly less pronounced compared to cells with mutant KRAS.”
ResultOvercoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61 · cited 1×
“Combining the KRAS G12D inhibitor MRTX1133 with one or more immune checkpoint blockades was more effective than MRTX1133 as a single agent in a murine model of PDAC [132].”
BackgroundPost-translational modification of KRAS: potential targets for cancer therapy
Wang, W., Yuan, T., Qian, M., Yan, F., Yang, L., He, Q., Yang, B., Lu, J., & Zhu, H. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00542-y · Cited by 59
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57 · cited 1×
“Next, we discuss the methods and strategies cancers employ to resist KRAS inhibition.”
MethodKras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Salmón, M., Álvarez-Díaz, R., Fustero-Torre, C., Brehey, O., Lechuga, C. G., Sanclemente, M., Fernández-García, F., López-García, A., Martín-Guijarro, M. C., Rodríguez-Perales, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164413 · Cited by 52 · cited 1×
“Early iterations of this compound were selective for the GDP-bound state, effectively locking KRAS G12C in its inactive form (Figure 3) [47].”
BackgroundCombination Therapies for the Optimisation of Bispecific T-Cell Engagers in Cancer Treatment
Zhu, W. M., & Middleton, M. R. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad013 · Cited by 46
Evolution of the market for mRNA technology
Xie, W., Chen, B., & Wong, J. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00147-y · Cited by 42 · cited 1×
“Next, we discuss the methods and strategies cancers employ to resist KRAS inhibition.”
MethodSecq, V., Villeret, J., Fina, F., Carmassi, M., Carcopino, X., Garcia, S., Metellus, I., Boubli, L., Iovanna, J., & Charpin, C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.794 · Cited by 40
Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
Pan, J., Zhang, Q., Sei, S., Shoemaker, R. H., Lubet, R. A., Wang, Y., & You, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19831 · Cited by 38 · cited 15×
“Monotherapy with the KRAS G12C inhibitor so-torasib increased the infiltration of T-cells, macrophages, and dendritic cells into tumors, sensitizing the TME to immunotherapy [48].”
BackgroundInfluentialThe Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Tria, S. M., Burge, M. E., & Whitehall, V. L. J. (2023) · Cancers · doi:10.3390/cancers15082375 · Cited by 38 · cited 1×
“Furthermore, the Shokat lab identified electrophiles with the potential for developing G12R-selective inhibitors [60].”
BackgroundRAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression
Sanclemente, M., Nieto, P., García‐Alonso, S., Fernández-García, F., Esteban-Burgos, L., Guerra, C. E., Drosten, M., Caleiras, E. J., Martinez-Torrecuadrada, J. L., Santamaría, D., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.008 · Cited by 37 · cited 1×
“Pathways downstream of KRAS ultimately promote proliferation and cell survival, which are key to the growth and maintenance of cancer cells when KRAS is inappropriately activated.”
BackgroundKSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors
Paniagua, G., Jacob, H. K. C., Brehey, O., García‐Alonso, S., Lechuga, C. G., Pons, T., Musteanu, M., Guerra, C., Drosten, M., & Barbacid, M. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13213 · Cited by 34 · cited 1×
“Drug-Tolerant Persister (DTP) cells can derive from pre-treatment stochastic expression variability in cell populations, or from treatment-induced changes in transcriptional profiles or epigenetic markers [115,117,118].”
BackgroundDong, X.-D., Zhang, M., Cai, C.-Y., Teng, Q.-X., Wang, J.-Q., Fu, Y.-G., Cui, Q., Patel, K., Wang, D.-T., & Chen, Z.-S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.843829 · Cited by 29 · cited 1×
“A range of promising strategies is being actively investigated and may prove to enhance long-term efficacy and decrease relapses.”
BackgroundNon-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit
Ning, W., Marti, T. M., Dorn, P., & Peng, R.-W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004669 · Cited by 29 · cited 1×
“Furthermore, the inhibition of KRAS can activate MRAS in a YAP-dependent manner, leading to a more mesenchymal marker profile [126].”
BackgroundZeng, C., Xing, W., & Liu, Y. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28515 · Cited by 25 · cited 1×
“These vaccines are designed to induce antigen-presenting cells to display mutant KRAS, stimulating attacks by cytotoxic T-cells against cancer cells expressing mutant KRAS neoantigen [78–80].”
BackgroundThe promise and peril of KRAS G12C inhibitors
Moore, A. R., & Malek, S. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.011 · Cited by 25
Muscarella, P., Bekaii-Saab, T., McIntyre, K., Rosemurgy, A., Ross, S. B., Richards, D. A., Fisher, W. E., Flynn, P. J., Mattson, A., Coeshott, C., et al. (2021) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2020.0021 · Cited by 24 · cited 1×
“Adoptive T-cell therapy has emerged as a promising approach for the treatment of KRAS-mutant cancers.”
BackgroundSilencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA
Papke, B., Azam, S. H., Feng, A. Y., Gutierrez-Ford, C., Huggins, H., Pallan, P. S., Van Swearingen, A. E. D., Egli, M., Cox, A. D., Der, C. J., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00165 · Cited by 22
Chai, T. F., Manu, K. A., Casey, P. J., & Wang, M. (2020) · Oncogene · doi:10.1038/s41388-020-1364-7 · Cited by 20 · cited 1×
“In 2021, the FDA approved sotorasib for the treatment of adult patients with KRAS G12C-mutated NSCLC, while adagrasib received similar approval the following year [48,50–53].”
BackgroundThe Intricate Metabolism of Pancreatic Cancers
Camelo, F., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_5 · Cited by 19
TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC
Tammaccaro, S. L., Prigent, P., Le Bail, J.-C., Dos-Santos, O., Dassencourt, L., Eskandar, M., Buzy, A., Venier, O., Guillemot, J.-C., Veeranagouda, Y., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16040553 · Cited by 18 · cited 1×
“In HDAC5-rich tumors, these macrophages increase TGF β production, triggering pSMAD3/SMAD4 signaling in cancer cells, and bypassing the need for KRAS.”
BackgroundThe Intricate Metabolism of Pancreatic Cancers
Camelo, F. S., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_5 · Cited by 17 · cited 1×
“KRAS mutations most commonly occur at the 12th codon near the nucleotide-binding site, with less prevalent mutations occurring at codons 13, 61, and 146 within other catalytic domains (Figure 1b,c) [23].”
BackgroundShai, A., Galouk, E., Miari, R., Tareef, H., Sammar, M., Zeidan, M., Rayan, A., & Falah, M. (2022) · Oncology Letters · doi:10.3892/ol.2022.13250 · Cited by 15 · cited 1×
“The avidity of PNAs for a single strand of”
BackgroundKRASG12R-Independent Macropinocytosis in Pancreatic Cancer
Hobbs, G. A., & Der, C. J. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-94004-1_11 · Cited by 12 · cited 2×
“One of the main rewired metabolic pathways is glucose metabolism.”
BackgroundTargeting cancer’s sweet spot: UGP2 as a therapeutic vulnerability
Kim, S., Wolfe, A., & Kim, S. E. (2021) · Molecular & Cellular Oncology · doi:10.1080/23723556.2021.1990676 · Cited by 12 · cited 1×
“Additionally, a pan-KRAS CYPA-recruiting compound, RMC-6236, is currently undergoing clinical trial [64].”
BackgroundSelf-citationExploiting the intrinsic misfolding propensity of the KRAS oncoprotein
Janssen, K., Claes, F., Van de Velde, D., Wehbi, V. L., Houben, B., Lampi, Y., Nys, M., Khodaparast, L., Khodaparast, L., Louros, N., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214921120 · Cited by 10 · cited 1×
“This approach showed promise in a transgenic mouse model, where repeated vaccinations before and after the induction of KRAS G12D-driven lung tumors elicited a strong immune response.”
BackgroundSchwab, M. G. (1990) · Klinische Pädiatrie · doi:10.1055/s-2007-1025519 · Cited by 5
Rothman, J. H., Surriga, O., de Stanchina, E., Vasudeva, S. D., & Schwartz, G. K. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.34 · Cited by 4 · cited 1×
“The avidity of PNAs for a single strand of”
BackgroundPatterson, M. (2000) · Nature Reviews Genetics · doi:10.1038/35042031 · Cited by 1
Research works printed but not linked: 1
- Weinberg, R.A. (2014). The Biology of Cancer, Garland Science, Taylor & Francis Group, LLC. [2nd ed.].
Cited by
Tian, L., Li, H., Cui, H., Tang, C., Zhao, P., Wang, X., & Cheng, Y. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08101-1 · Cited by 31
“However, KRAS is not sensitive to the inhibition of upstream growth factor receptor signaling, while targeting downstream effector molecules is hindered by the activation of compensatory resistance mechanisms [3, 4].”
Wang, Q., Ouyang, H., Li, W., Zhang, H., He, A., & Liu, R. (2025) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2025.136624 · Cited by 14
Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles
Vetma, V., Puoti, I., Karolak, N. K., Chakraborti, S., Diers, E., Girardi, E., Khan, S., Kidd, G., Kropatsch, K., McLennan, R., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c10354 · Cited by 20
Nalawansha, D. A., Mazis, G., Husemoen, G., Ashton, K. S., Deng, W., Wurz, R. P., Tran, A. T., Lanman, B. A., Xie, J., Guenette, R. G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63128-4 · Cited by 19
“EmergingresistancetoKRASinhibitors(KRASi)isacriticalchallengein maximizing the clinical potential of these drugs 40 – 43 .”
HRS-4642: The next piece of the puzzle to keep KRAS in check
Flores-Gómez, A. A., & Drosten, M. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.005 · Cited by 17
Metadata
- Authors
- Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L.
- Affiliations
- The Graduate Center, CUNY (US)
- City University of New York (US)
- Corresponding author
- Wolfe, Andrew L.
- Venue
- Current Oncology
- Publisher
- MDPI AG
- Published
- 2024-04-03
- Volume
- 31
- Issue
- 4
- Pages
- 2024-2046
- ISSN
- 1198-0052 (ISSN-L)
- 1718-7729
- PMC
- PMC11049385
- OpenAlex
- W4393869729
- Cited by
- 68
- References
- 144
- Citations by year
- 2026: 39 · 2025: 23 · 2024: 6
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Current Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Cancer Institute (R00CA226363, DRG2214-15)
- Hunter College of the City University of New York (R00CA226363, DRG2214-15)
- Oncogenuity, Inc. (R00CA226363, DRG2214-15)
- Damon Runyon Cancer Research Foundation (R00CA226363, DRG2214-15)
- Graduate Center of the City University of New York (R00CA226363, DRG2214-15)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS, small GTPases, oncogenic KRAS mutations, KRAS inhibitors, drug resistance mechanisms, pan-KRAS inhibitors, PROTACs, siRNA, peptide nucleic acid, copy number alterations, alternative signaling pathways, epigenetic resistance, tumor microenvironment, cancer therapy
- MeSH terms
- Antineoplastic Agents, Humans, Mutation, Neoplasms, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.